Prescribing information and Adverse event reporting can be found at the bottom of the page
With rising abortion rates, particularly among all ages 25 and above, the largest increase are amongst women aged 30. Therefore, there is a clear need to offer the most effective contraceptive methods.1 In a quantitative survey of over 430 women and their experiences of unintended pregnancy and abortion, over half were using contraception at the time they became pregnant.2 Long-acting methods can be the most effective form of contraception because they do not rely on user compliance.3
Here you will find resources to guide conversations with your patients, helping to identify which is the most suitable contraception for them.
For every 100 women that choose to take the pill this year, nine could become pregnant due to missed-pill moments.2 Long-acting methods such as intrauterine systems (IUS) offer birth control with the highest available efficacy and are one of the most effective contraceptive methods because their effectiveness is independent of user compliance.3
Jaydess®▼1 13.5mg intrauterine delivery system (levonorgestrel) |
Kyleena®2 19.5mg intrauterine delivery system (levonorgestrel) |
Mirena®3 52mg intrauterine delivery system (levonorgestrel) |
|
---|---|---|---|
Indication | Contraception for up to 3 years | Contraception for up to 5 years | Contraception for up to 5 years Treatement of HMB for up to 5 years endometrial protection during HRT for 4 years |
Pearl Index (efficacy) | Year 1:0.41 3-years: 0:33 |
Year 1: 0.16 5-years: 0.29 |
Year 1: 0.2 Years 5: 0.144 |
Contraceptive failure rate | 0.4% at 1 year 0.9% over 3 years |
0.2% at 1 year 1.4% over 5 years |
0.2% at 1 year 0.7% over 5 years |
Total levonorgestrel (LNG) content (mg) | 13.5 | 19.5 | 52 |
Average in vivo LNG release rate over the first year of use | 8 μg/24 hours | 12.6 μg/24 hours2 | 20 μg/24 hours* |
% of women experiencing amenorrhoea and infrequent bleeding at 1 year post insertion | Amenorrhoea: 6% infrequent bleeding: 20% |
Amenorrhoea: 12% infrequent bleeding: 26% |
Amenorrhoea: 16% infrequent bleeding: 57% |
T-frame size (mm) | 28 × 30 | 28 × 30 | 32 × 324 |
Placement tube diameter size (mm) | 3.8 | 3.8 | 4.4 |
Colour of monofilament threads | Brown | Blue | Brown |
Differentiator in imaging techniques:silver ring | Improved visibility on ultrasound | Improved visibility on ultrasound | - |
PP-PF-WHC-GB-1033 May 2022
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.